



## Clinical trial results:

### A multicenter non-randomized phase II study to evaluate nab-paclitaxel in metastatic breast cancer patients failing a solvent based taxane as (neo-)adjuvant treatment

#### Summary

EudraCT number	2011-000075-13
Trial protocol	DE
Global end of trial date	20 September 2013

#### Results information

Result version number	v1 (current)
This version publication date	18 December 2021
First version publication date	18 December 2021
Summary attachment (see zip file)	TIFFANY CSR Synopse (GBG 65 - TIFFANY Clinical Study Report - Version 1 (04.12.2013) Synopsis.pdf)

#### Trial information

##### Trial identification

Sponsor protocol code	GBG65
-----------------------	-------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01416558
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	GBG Forschungs GmbH
Sponsor organisation address	Martin Behaim Str. 12, Neu-Isenburg, Germany,
Public contact	Medicine and Research, GBG Forschungs GmbH, +49 610274800, publications@gbg.de
Scientific contact	Medicine and Research, GBG Forschungs GmbH, +49 610274800, publications@gbg.de

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	13 September 2013
Is this the analysis of the primary completion data?	Yes
Primary completion date	20 September 2012
Global end of trial reached?	Yes
Global end of trial date	20 September 2013
Was the trial ended prematurely?	Yes

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To determine overall response rate (ORR) and to exclude that it is 20% or lower.

Protection of trial subjects:

The trial protocol including amendments, the patient information and the informed consent were reviewed and approved from a properly constituted IRB/IEC for each site prior to the study start. The trial was in compliance with the International Conference on Harmonization (ICH) - Harmonized Tripartite Guideline for Good Clinical Practice (GCP) (E6), and the Commission Directives in the European Community as well as with the applicable German national laws and regulations, and with Declaration of Helsinki and its revisions in all aspects of preparation, monitoring, reporting, auditing, and archiving. IDMC was to ensure the ethical conduct of the trial and to protect patients' safety interests in this study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 September 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Germany: 5
Worldwide total number of subjects	5
EEA total number of subjects	5

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	5
From 65 to 84 years	0

85 years and over	0
-------------------	---

## Subject disposition

### Recruitment

Recruitment details:

The IDMC recommended to close the TIFFANY study prematurely due to slow recruitment (5 patients in 11 months). None of the measures to stimulate recruitment, such as training, amendment were able boost the recruitment to finalise the study.

### Pre-assignment

Screening details:

Patients with metastatic HER2-positive and negative breast cancer failing primary therapy with a solvent based taxane as (neo-)adjuvant therapy.

### Period 1

Period 1 title	Recruitment period (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Arm title	nab-paclitaxel
-----------	----------------

Arm description:

nab-Paclitaxel  
125 mg/m<sup>2</sup> weekly in 5 of 6 weeks i.v.

Arm type	Experimental
Investigational medicinal product name	nab-Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

125 mg/m<sup>2</sup> weekly in 5 of 6 weeks i.v.

Number of subjects in period 1	nab-paclitaxel
Started	5
Completed	3
Not completed	2
non-hematological tox. related to study medication	1
Physician decision	1

## Baseline characteristics

### Reporting groups

Reporting group title	Recruitment period
-----------------------	--------------------

Reporting group description: -

Reporting group values	Recruitment period	Total	
Number of subjects	5	5	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: years			
median	50		
full range (min-max)	44 to 56	-	
Gender categorical			
Units: Subjects			
Female	5	5	
Male	0	0	

## End points

### End points reporting groups

Reporting group title	nab-paclitaxel
Reporting group description: nab-Paclitaxel 125 mg/m2 weekly in 5 of 6 weeks i.v.	

### Primary: Overall response rate (ORR)

End point title	Overall response rate (ORR) <sup>[1]</sup>
End point description: This analysis is mainly descriptive. Due to the premature closure of the study, the planned test for the primary endpoint does not have the assumed power of 80%.	
End point type	Primary
End point timeframe: ORR is defined as complete response (CR) or partial response (PR) according to modified RECIST criteria. Clinical benefit rate (CBR) is defined as CR, PR or stable disease for at least 24 weeks in patients with measurable disease	

#### Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This analysis is mainly descriptive. Due to the premature closure of the study, the planned test for the primary endpoint does not have the assumed power of 80%.

End point values	nab-paclitaxel			
Subject group type	Reporting group			
Number of subjects analysed	5			
Units: percent				
number (not applicable)				
Partial response	1			
Stable disease	2			
Progressive disease	2			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All adverse events occurring during the study treatment period were reported.

Adverse event reporting additional description:

Predefined AEs any grade (1-4) are reported per Patient.

For SAEs relatedness was not tabulated, therefore here we conservatively record all SAEs as related to treatment

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	n.a.
-----------------	------

Dictionary version	1
--------------------	---

### Reporting groups

Reporting group title	All patients
-----------------------	--------------

Reporting group description: -

Serious adverse events	All patients		
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 5 (40.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Gastrointestinal disorders			
Gastrointestinal upset			
subjects affected / exposed	1 / 5 (20.00%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pleural effusion, Dyspnea			
subjects affected / exposed	1 / 5 (20.00%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	1 / 5 (20.00%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	All patients		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 5 (100.00%)		
Investigations			
Alkaline phosphatase			
subjects affected / exposed	1 / 5 (20.00%)		
occurrences (all)	1		
ASAT			
subjects affected / exposed	1 / 5 (20.00%)		
occurrences (all)	1		
ALAT			
subjects affected / exposed	2 / 5 (40.00%)		
occurrences (all)	2		
LH i.S.			
subjects affected / exposed	2 / 5 (40.00%)		
occurrences (all)	2		
Bilirubin			
subjects affected / exposed	1 / 5 (20.00%)		
occurrences (all)	1		
Hypophosphatemia			
subjects affected / exposed	1 / 5 (20.00%)		
occurrences (all)	1		
high value LDL	Additional description: reported as free-text		
subjects affected / exposed	2 / 5 (40.00%)		
occurrences (all)	2		
Increased transaminasis	Additional description: reported as free-text		
subjects affected / exposed	2 / 5 (40.00%)		
occurrences (all)	2		
Vascular disorders			
Flush	Additional description: reported as free-text		
subjects affected / exposed	2 / 5 (40.00%)		
occurrences (all)	2		
Nervous system disorders			



peripheral sensory neuropathy subjects affected / exposed occurrences (all)	2 / 5 (40.00%) 2		
peripheral motor neuropathy subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1		
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	4 / 5 (80.00%) 4		
Leucopenia subjects affected / exposed occurrences (all)	3 / 5 (60.00%) 3		
Neutropenia subjects affected / exposed occurrences (all)	3 / 5 (60.00%) 3		
General disorders and administration site conditions			
Fatigue subjects affected / exposed occurrences (all)	3 / 5 (60.00%) 3		
Fever	Additional description: without grade 3/4 neutropenia		
subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1		
Ear and labyrinth disorders			
Vertigo	Additional description: reported as free-text		
subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1		
Gastrointestinal disorders			
Nausea subjects affected / exposed occurrences (all)	2 / 5 (40.00%) 2		
Vomiting subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1		
Mucositis			

subjects affected / exposed	1 / 5 (20.00%)		
occurrences (all)	1		
Diarrhoea			
subjects affected / exposed	1 / 5 (20.00%)		
occurrences (all)	1		
Dental inflammation	Additional description: reported as free-text		
subjects affected / exposed	2 / 5 (40.00%)		
occurrences (all)	2		
Respiratory, thoracic and mediastinal disorders			
Dry cough	Additional description: reported as free-text		
subjects affected / exposed	1 / 5 (20.00%)		
occurrences (all)	1		
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	5 / 5 (100.00%)		
occurrences (all)	5		
Rash			
subjects affected / exposed	1 / 5 (20.00%)		
occurrences (all)	1		
Onycholysis	Additional description: reported as free-text		
subjects affected / exposed	3 / 5 (60.00%)		
occurrences (all)	3		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 5 (20.00%)		
occurrences (all)	1		
Myalgia			
subjects affected / exposed	1 / 5 (20.00%)		
occurrences (all)	1		
Bone pain	Additional description: reported as free-text		
subjects affected / exposed	1 / 5 (20.00%)		
occurrences (all)	1		
Infections and infestations			
Infection	Additional description: without grade 3/4 neutropenia		
subjects affected / exposed	3 / 5 (60.00%)		
occurrences (all)	3		



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
10 February 2012	Protocol (Version 4, 10.02.2012), Amendment 1: inclusion criterion: "• ASAT (SGOT) and ALAT (SGPT) $\leq 2.5 \times$ ULN (concomitant elevations in serum bilirubin and ASAT/ALAT above $1.0 \times$ ULN are not permitted)." was deleted. Patients could be included with relapse $\leq 24$ months after (neo)adjuvant solvent taxane based therapy (instead of $\leq 12$ months)

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
02 November 2012	The IDMC recommended to close the TIFFANY study prematurely due to slow recruitment (5 patients in 11 months)	-

Notes:

### Limitations and caveats

None reported